ICYMI, some of this week’s featured content includes the ACP encouraging all vaccinations, video interviews diet and supplement in psoriasis treatment, articles on safety, efficacy study results for abrocitinib, SCALE conference coverage and more.
An expected rise in COVID-19 cases in combination with other preventable diseases could overwhelm the healthcare system.
A phase 3 trial studied the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis in teens.
In this video interview, Marc Serota, MD, discusses his research regarding type 2 inflammation, the future of treating it as 1 condition or 2, and why physicians should educate their patients about this type of inflammation.
Curcumin has a long history as an effective treatment for everything from chronic pain to skin infections. Nanoparticle encapsulation shows promise in meeting that challenge and opening the way for a safe, effective adjuvant to sunscreen.
A study published in the Dermatol Ther (Heidelb) journal performed an investigational overview on estrogens and their impact on health while explaining how this leads to cosmeceuticals for female patients with estrogen-deficient skin.
The share of physicians in private practice has dropped below 50 percent.
Though investigators called for more research on the biologic, recent data showed patients treated with bimekizumab recorded improved skin pain when compared to placebo and adalimumab.
UCB announced the European Commission have granted marketing authorization for bimekizumab for the treatment of moderate to severe plaque psoriasis.
Part 1 of Dermatology Times®’ coverage of a strategic look at superficial radiation therapy (SRT) presented at the recent Music City SCALE Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting in Nashville, Tennessee, showcases this therapy’s efficacy in treating keratinocytic skin cancers.
In this video interview, Monica Bonakdar, MD, shares her thoughts on combination therapies, how COVID-19 affected her practice, and more.
There are an increasing number of novel immunotherapies available for patients with skin cancer, however, their numerous adverse events must be addressed.
Upadacitinib has been approved by the European Commision and becomes the first Janus kinase (JAK) inhibitor approved in the European Union for the treatment of moderate to severe atopic dermatitis in adult and pediatric patients.
Many conditions are different in the pediatric population than in the adult population. How does hidradenitis suppurativa differ between the 2 groups?
It has been 20 years since the FDA approved a new sunscreen filter. However, a recent study evaluating curcumin could change that.
Part 2 of Dermatology Times®’ coverage of a strategic look at superficial radiation therapy (SRT) presented at the recent Music City SCALE Symposium for Cosmetic Advances & Laser Education 16th Annual Meeting details this therapy’s potential for reducing keloid recurrence.
A jump in new COVID-19 cases dropped margins and volumes.
185,000 adults with confirmed cases of COVID-19 were hospitalized in June and July. Of those, 182,000, or 98.3%, had not been vaccinated for the disease.